decisionhealth Newsletters, Answer Books - 2008 Issue 5 (May)
National_Coverage_Determinations_Manual / TUMOR_ANTIGEN_BY_IMMUNOASSAY_CA_19
Subscribe or sign in to view the full article.
Article Overview
This page presents a Medicare National Coverage Determinations Manual policy on tumor antigen testing by immunoassay for CA 19-9. It is relevant to clinicians, coders, and billing staff who need to understand the general coverage scope, the types of patients and clinical scenarios addressed, and the policy’s stated limitations. The article focuses on when the test is discussed in relation to monitoring established malignancies and treatment response, as well as when the service is not covered.
Why This Topic Matters
Coverage policies for laboratory tumor marker testing affect whether claims are payable and whether documentation supports medical necessity. Understanding the scope of this policy helps users determine if the article applies to their billing, coding, or clinical review workflow.
What You Will Learn
- The policy area covered by the CA 19-9 tumor antigen immunoassay article
- The clinical contexts discussed for tumor marker monitoring
- The general coverage limitations described in the policy
- How the article frames use of the test in relation to malignancy follow-up and treatment response
Who Should Read This
- Medical coders
- Billing staff
- Compliance teams
- Clinicians
- Revenue cycle professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com